Simcere Pharmaceutical Group Limited (2096) Issues FY2025 Profit Alert

Bulletin Express02-25

Simcere Pharmaceutical Group Limited (2096) announced a profit alert for the fiscal year ended December 31, 2025 (FY2025). According to a preliminary assessment of the unaudited consolidated management accounts, revenue is expected to reach RMB7.70 billion to RMB7.80 billion, reflecting an increase of approximately 16.0% to 17.6% over the RMB6.64 billion recorded in the prior year.

Profit attributable to equity shareholders is anticipated to be in the range of RMB1.30 billion to RMB1.40 billion, an increase of approximately 80.1% to 93.9% compared to the restated RMB0.72 billion in FY2024. Meanwhile, adjusted profit attributable to equity shareholders is projected at RMB1.25 billion to RMB1.35 billion, representing an increase of approximately 24.1% to 34.1% over the restated adjusted profit of RMB1.01 billion for FY2024.

The restatement of the FY2024 financial statements arises from the Group’s application of merger accounting principles to its acquisition of Xianwei (Hainan) Biotechnology Co., Ltd. in October 2025. The final results for FY2025 remain subject to potential adjustments and are slated for publication in late March 2026. The company has advised shareholders and potential investors to exercise caution when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169652560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169652560","market":"us","top_or_hot":-1,"title":"Simcere Pharmaceutical Group Limited (2096) Issues FY2025 Profit Alert","media":"Bulletin Express","content":"<p>Simcere Pharmaceutical Group Limited (2096) announced a profit alert for the fiscal year ended December 31, 2025 (FY2025). According to a preliminary assessment of the unaudited consolidated management accounts, revenue is expected to reach RMB7.70 billion to RMB7.80 billion, reflecting an increase of approximately 16.0% to 17.6% over the RMB6.64 billion recorded in the prior year.</p>\n<p>Profit attributable to equity shareholders is anticipated to be in the range of RMB1.30 billion to RMB1.40 billion, an increase of approximately 80.1% to 93.9% compared to the restated RMB0.72 billion in FY2024. Meanwhile, adjusted profit attributable to equity shareholders is projected at RMB1.25 billion to RMB1.35 billion, representing an increase of approximately 24.1% to 34.1% over the restated adjusted profit of RMB1.01 billion for FY2024.</p>\n<p>The restatement of the FY2024 financial statements arises from the Group’s application of merger accounting principles to its acquisition of Xianwei (Hainan) Biotechnology Co., Ltd. in October 2025. The final results for FY2025 remain subject to potential adjustments and are slated for publication in late March 2026. The company has advised shareholders and potential investors to exercise caution when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Group Limited (2096) Issues FY2025 Profit Alert</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Group Limited (2096) Issues FY2025 Profit Alert\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-25 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Simcere Pharmaceutical Group Limited (2096) announced a profit alert for the fiscal year ended December 31, 2025 (FY2025). According to a preliminary assessment of the unaudited consolidated management accounts, revenue is expected to reach RMB7.70 billion to RMB7.80 billion, reflecting an increase of approximately 16.0% to 17.6% over the RMB6.64 billion recorded in the prior year.</p>\n<p>Profit attributable to equity shareholders is anticipated to be in the range of RMB1.30 billion to RMB1.40 billion, an increase of approximately 80.1% to 93.9% compared to the restated RMB0.72 billion in FY2024. Meanwhile, adjusted profit attributable to equity shareholders is projected at RMB1.25 billion to RMB1.35 billion, representing an increase of approximately 24.1% to 34.1% over the restated adjusted profit of RMB1.01 billion for FY2024.</p>\n<p>The restatement of the FY2024 financial statements arises from the Group’s application of merger accounting principles to its acquisition of Xianwei (Hainan) Biotechnology Co., Ltd. in October 2025. The final results for FY2025 remain subject to potential adjustments and are slated for publication in late March 2026. The company has advised shareholders and potential investors to exercise caution when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1169652560","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169652560","pubTimestamp":1772011538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Simcere Pharmaceutical Group Limited (2096) announced a profit alert for the fiscal year ended December 31, 2025 (FY2025). According to a preliminary assessment of the unaudited consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"先声药业集团有限公司(2096)发布2025财年盈利预警","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Simcere Pharmaceutical Group Limited (2096) announced a profit alert for the fiscal year ended December 31, 2025 (FY2025). According to a preliminary assessment of the unaudited consolidated management accounts, revenue is expected to reach RMB7.70 billion to RMB7.80 billion, reflecting an increase of approximately 16.0% to 17.6% over the RMB6.64 billion recorded in the prior year.\nProfit attributable to equity shareholders is anticipated to be in the range of RMB1.30 billion to RMB1.40 billion, an increase of approximately 80.1% to 93.9% compared to the restated RMB0.72 billion in FY2024. Meanwhile, adjusted profit attributable to equity shareholders is projected at RMB1.25 billion to RMB1.35 billion, representing an increase of approximately 24.1% to 34.1% over the restated adjusted profit of RMB1.01 billion for FY2024.\nThe restatement of the FY2024 financial statements arises from the Group’s application of merger accounting principles to its acquisition of Xianwei (Hainan) Biotechnology Co., Ltd. in October 2025. The final results for FY2025 remain subject to potential adjustments and are slated for publication in late March 2026. The company has advised shareholders and potential investors to exercise caution when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169652560","isCrawlerRequest":true}